Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease

NCT03036813 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03036813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03036813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2016
Completion date
October 8, 2019
Enrollment
449 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease